Deliver Your News to the World

Spectral Diagnostics Inc. Ships Innovative i-Lynx’TM’ Connectivity Instrument


WEBWIRE

TORONTO -- January 25, 2005 -- Spectral Diagnostics Inc. (TSX:SDI) announced today the first shipment of its new i-Lynx(TM) connectivity solution. The i-Lynx(TM) system consists of two interfaced components; a novel handheld electronic device to capture and analyze an image from the current Cardiac STATus(R) rapid test strip, and a local area network (LAN) compatible docking station to automate data capture and communication.

The i-Lynx(TM) handheld is a battery powered portable instrument that accompanies the Cardiac STATus(R) rapid test to the patient’s bedside. The unit contains an interactive PDA-style color touch screen and a built-in barcode scanner that allows for easy user interface. The custom software enables laboratories to implement and monitor all required quality assurance procedures even at a decentralized testing location such as an emergency department. The i-Lynx(TM) docking station has integral printing and LAN communication capabilities that automate the collection and transfer of critical patient testing data.

Dr. Paul M. Walker, President and CEO at Spectral said: “As an added value to the Cardiac STATus(R) testing platform, the i-Lynx(TM) system adds previously unavailable features important to both the laboratory and Point-of-Care (POC) testing staff without sacrificing the delivery of time sensitive test information. We are excited by this important milestone in the Company’s ongoing efforts to provide rapid diagnostic information capable of guiding critical therapy”.

The initial instrument application will be part of the Company’s current Cardiac STATus(R) POC testing system. Many of the Company’s future rapid tests will also be compatible with the i-Lynx(TM) system.

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products are rapid format tests measuring markers of myocardial infarction (Cardiac STATus(R)). New products include rapid diagnostics for sepsis (the Endotoxin Activity Assay). Spectral manufactures the EAATM and Cardiac STATus(R). Spectral’s common shares are listed on The Toronto Stock Exchange: SDI.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the completion of the proposed offering, the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.



WebWireID1183





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.